Conclusively, the administration of CD19 CAR-T cell therapy five days post cyclophosphamide and fludarabine preconditioning emerged as the most potent therapeutic strategy against B-ALL. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.